CN111001033A - High-efficiency hemostatic and preparation method thereof - Google Patents
High-efficiency hemostatic and preparation method thereof Download PDFInfo
- Publication number
- CN111001033A CN111001033A CN202010015102.6A CN202010015102A CN111001033A CN 111001033 A CN111001033 A CN 111001033A CN 202010015102 A CN202010015102 A CN 202010015102A CN 111001033 A CN111001033 A CN 111001033A
- Authority
- CN
- China
- Prior art keywords
- powder
- hemostatic
- particle size
- parts
- hemostatic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of hemostatic agents and preparation thereof, and discloses a high-efficiency hemostatic agent and a preparation method thereof. The hemostatic agent is prepared by mixing raw materials with mild characteristics, such as strong selective adsorption capacity, good permeability, good blood coagulation performance and the like. Through the interaction between the raw materials, the mutual fusion and the effective compatibility mode, the effects of diminishing inflammation, inhibiting bacteria, clearing heat and relieving pain are achieved, the rapid hemostasis, the improvement of the coagulation reaction rate, the increase of the stability of the hemostasis effect, the rapid heat dissipation, the reduction of the high-temperature burn rate and the acceleration of the healing of wound muscles can be realized in a shorter time after the hemostatic agent is contacted with the wound surface, the secondary injury is effectively avoided, and the effective rate of the wound treatment is improved. The preparation method has the advantages of simple operation process, less operation equipment, low requirement on operators, moderate cost, safety and reliability, and is suitable for any individual.
Description
Technical Field
The invention belongs to the technical field of hemostatic agents and preparation thereof, and particularly relates to a high-efficiency hemostatic agent and a preparation method thereof.
Background
At present, the traditional preschool wound bleeding hemostatic products comprise medical gauze, tourniquets, wound plasters, hemostatic bags and the like, are widely applied to the fields of troops, fire fighting, emergency treatment centers, public security, frontier defense, field exploration, household emergency first aid and the like, are essential hemostatic products for dealing with the occurrence of wound bleeding under accident conditions in petroleum, coal mines, public transportation and personnel centralized public places, and play an important role in disaster recourse (such as earthquake and explosion) and emergency bleeding of sudden traffic accidents. However, the products have certain defects in the using process, and when the medical gauze is used, a large compression force needs to be applied to a wound bleeding position, so that the hemostatic effect is poor; the wound plaster is suitable for hemostasis of small wounds, and has poor hemostatic effect; the packing bag of the hemostatic bag coated with the hemostatic particles is attached to the wound surface of a patient, which can cause secondary skin injuries of the patient, such as allergy, incapability of removing subsequent packing after adhesion with the wound skin, and the like, and the packing bag is very easy to adsorb blood on the wound surface, so that a blood loss state within a period of time is caused, and the influence of dizziness on the head of the patient is caused.
In order to obtain an optimal hemostatic agent, new hemostatic technologies have been developed in recent years, including the use of functional liposomes, block copolymers, synthetic platelets and nanomaterials. Wherein, the hemostatic agent of the nano-grade material has larger clinical application value due to good hemostatic effect and flexible and diverse use. However, these hemostatic agents cannot achieve the requirements of quick hemostasis, disinfection and sterilization, heat clearing and pain relieving, and no secondary damage to the wound surface, and the problem becomes an urgent problem to be solved.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide a high-efficiency hemostatic and a preparation method thereof.
The technical scheme adopted by the invention is as follows: the efficient hemostatic is prepared from the following raw materials in parts by mass:
70-120 parts of zeolite powder, 0.08-2 parts of graphene powder, 0.2-1.5 parts of silver powder and 0.02-0.22 part of water-soluble menthol powder;
preferably, the hemostatic is prepared from the following raw materials in parts by mass:
90-112 parts of zeolite powder, 0.1-1.5 parts of graphene powder, 0.4-1 part of silver powder and 0.08-0.20 part of water-soluble menthol powder;
preferably, the hemostatic is prepared from the following raw materials in parts by mass:
98 parts of zeolite powder, 1 part of graphene powder, 0.8 part of silver powder and 0.15 part of water-soluble menthol powder.
The hemostatic agent is prepared by mixing raw materials with strong selective adsorption capacity, good permeability, good blood coagulation performance and mild characteristics. The hemostatic agent achieves the effects of diminishing inflammation, inhibiting bacteria, clearing heat and relieving pain by mutual interaction and mutual fusion and effective compatibility of the raw materials, so that quick hemostasis, improvement of coagulation reaction rate, increase of stability of hemostasis effect, quick heat dissipation, reduction of high-temperature burn rate and acceleration of wound healing after the hemostatic agent is contacted with a wound can be achieved in a short time, secondary injury is effectively avoided, and the wound treatment efficiency is improved. The hemostatic agent is safe and reliable, and is suitable for any individual.
Preferably, the zeolite powder comprises clinoptilolite powder.
Zeolite is an aqueous alkali or alkaline earth metal aluminosilicate mineral. Since zeolite has many properties such as adsorptivity, ion-exchange property, catalysis, acid resistance and heat resistance, it is widely used as an adsorbent, ion exchanger and catalyst, and also used for drying and purifying gas and treating sewage. Zeolites are used in the medical field for measuring the amount of nitrogen in blood and urine. The zeolite is also developed into health care products for resisting aging and removing heavy metals accumulated in the body. The zeolite has the characteristics of large distribution amount and easy exploitation.
Preferably, the zeolite powder has a particle size of 1-1000 μm, preferably 300-850 μm, and more preferably 550 μm.
Preferably, the particle size of the graphene powder is 10 to 100 μm, preferably 20 to 75 μm, and more preferably 50 μm.
The silver powder preferably has a particle diameter of 0.1 to 1 μm, preferably 0.3 to 0.8 μm, and more preferably 0.45 μm.
The particle size of the water-soluble menthol powder is preferably 0.1 to 1 μm, more preferably 0.3 to 0.8 μm, and still more preferably 0.45. mu.m.
Graphene (Graphene), a carbon atom sp2The hexagonal honeycomb-shaped two-dimensional carbon nanomaterial consists of hybrid tracks. The graphene has excellent optical, electrical and mechanical properties, and can be processed in materials science and micro-nano processing,has important application prospect in the aspects of energy, biomedicine, drug delivery and the like. Common methods for producing graphene powder are a mechanical stripping method, a redox method, a SiC epitaxial growth method and a chemical vapor deposition method. Graphene has very good thermal conductivity. Pure defect-free single-layer graphene has a thermal conductivity as high as 5300W/mK, and is the carbon material with the highest thermal conductivity up to now.
Silver powder, which has a very high surface activity and catalytic performance, and is used widely in catalysts and diluents for ultra-low temperature refrigerants. Meanwhile, the superfine silver powder has the effects of disinfection and sterilization, has excellent disinfection and sterilization effects under the condition of small using amount, realizes disinfection and sterilization of wound surfaces needing hemostasis, and can quickly promote tissue regeneration and heal the wound surfaces under the aseptic condition.
The water-soluble menthol powder is prepared by modifying a water-insoluble menthol living mint oil product into a stable hydrate which can form dynamic association such as coordination, compounding, hydration and the like with water by using a W-SP series efficient direct solvent with extremely strong hydrophilicity by using a modern ultramicro emulsification direct dissolving technology. The produced water-soluble menthol and water-soluble peppermint oil can not only achieve the aim of direct water solubility, but also have unique synergistic function promoting effects in the aspects of improving the use effect, biochemical performance, fine and smooth sense, transparent appearance, quality stability and the like of the water-based perfumed product.
A preparation method of a high-efficiency hemostatic comprises the steps of selecting zeolite powder, graphene powder, silver powder and water-soluble menthol powder according to corresponding proportions, mixing and sterilizing to obtain a finished product.
The preparation method of the hemostatic provided by the invention has the advantages that on the basis of carrying out fusion and good preservation on the effective components of the raw materials to the maximum extent after finely selecting the materials, the operation process is simple and convenient, the operation equipment is few, the requirement on operators is not high, the cost is moderate, and the preparation method is safe and reliable.
Preferably, the mixing temperature comprises 20-35 degrees celsius, preferably 25-32 degrees celsius, further preferably 30 degrees celsius.
Preferably, the mixing period comprises 10 to 35 minutes, preferably 15 to 30 minutes, and more preferably 20 minutes.
Preferably, the sterilization includes one or more of radiation sterilization, dry sterilization, and high temperature steam sterilization.
The invention has the beneficial effects that:
the present invention provides a highly effective hemostatic agent prepared by mixing raw materials having a strong selective adsorption ability, a good permeability, a good blood coagulation property and the like and having mild characteristics. The hemostatic agent achieves the effects of diminishing inflammation, inhibiting bacteria, clearing heat and relieving pain by mutual interaction and mutual fusion and effective compatibility of the raw materials, so that quick hemostasis, improvement of coagulation reaction rate, increase of stability of hemostasis effect, quick heat dissipation, reduction of high-temperature burn rate and acceleration of wound healing after the hemostatic agent is contacted with a wound can be achieved in a short time, secondary injury is effectively avoided, and the wound treatment efficiency is improved. The hemostatic agent is safe and reliable, and is suitable for any individual. The preparation method of the hemostatic has the advantages of simple and rapid operation process, less operation equipment, low requirement on operators and moderate cost on the basis of maximally fusing and well storing the effective components of the raw materials after finely selecting the materials.
Detailed Description
The present invention is further illustrated below with reference to specific examples. It will be appreciated by those skilled in the art that the following examples, which are set forth to illustrate the present invention, are intended to be part of the present invention, but not to be construed as limiting the scope of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The examples were carried out under the conventional conditions, unless otherwise specified. The reagents used are all conventional products which are commercially available.
Example 1:
according to the corresponding proportion, 70 g of clinoptilolite powder (with the grain diameter of 1000 mu m), 0.08 g of graphene powder (with the grain diameter of 10 mu m), 0.2 g of silver powder (with the grain diameter of 0.1 mu m) and 0.02 g of water-soluble menthol powder (with the grain diameter of 0.1 mu m) are selected, mixed and stirred for 10 minutes in a mixer (LongYu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufuji City), and then the mixture is placed into a vacuum packaging machine for packaging and then sterilized by a radiation sterilization mode to obtain the finished product.
Example 2:
according to the corresponding proportion, 70 g of clinoptilolite powder (with the particle size of 10 mu m), 0.08 g of graphene powder (with the particle size of 100 mu m), 0.2 g of silver powder (with the particle size of 1 mu m) and 0.02 g of water-soluble menthol powder (with the particle size of 1 mu m) are selected, mixed and stirred for 35 minutes in a mixer (Longdong Yu middle-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukan City), packaged in a vacuum packaging machine, and sterilized by radiation sterilization to obtain the finished product.
Example 3:
according to the corresponding proportion, 120 g of clinoptilolite powder (the particle size is 300 mu m), 2 g of graphene powder (the particle size is 20 mu m), 1.5 g of silver powder (the particle size is 0.3 mu m) and 0.22 g of water-soluble menthol powder (the particle size is 0.3 mu m) are selected, mixed and stirred for 10 minutes in a mixer (LongYu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukuai City), and then the mixture is placed into a vacuum packaging machine for packaging and then sterilized by a radiation sterilization mode to obtain the finished product.
Example 4:
according to the corresponding proportion, 120 g of clinoptilolite powder (with the grain diameter of 800 mu m), 2 g of graphene powder (with the grain diameter of 10 mu m), 1.5 g of silver powder (with the grain diameter of 0.3 mu m) and 0.22 g of water-soluble menthol powder (with the grain diameter of 0.3 mu m) are selected, mixed and stirred for 35 minutes in a mixer (Longyu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukan City), and then the mixture is placed into a vacuum packaging machine for packaging and then sterilized by a radiation sterilization mode, thus obtaining the finished product.
Example 5:
90 g of clinoptilolite powder (the particle size is 850 mu m), 0.1 g of graphene powder (the particle size is 100 mu m), 0.4 g of silver powder (the particle size is 0.8 mu m) and 0.08 g of water-soluble menthol powder (the particle size is 0.8 mu m) are selected according to corresponding proportions, mixed and stirred for 15 minutes in a mixer (LongYu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufu City), packaged in a vacuum packaging machine, and sterilized in a drying and sterilizing manner to obtain the finished product.
Example 6:
according to the corresponding proportion, 90 g of clinoptilolite powder (with the grain diameter of 550 mu m), 0.1 g of graphene powder (with the grain diameter of 20 mu m), 0.4 g of silver powder (with the grain diameter of 0.3 mu m) and 0.08 g of water-soluble menthol powder (with the grain diameter of 0.3 mu m) are selected, mixed and stirred for 30 minutes in a mixer (LongYu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufuji City), and then the mixture is placed into a vacuum packaging machine for packaging and then sterilized by a drying and sterilizing mode to obtain the finished product.
Example 7:
112 g of clinoptilolite powder (with the particle size of 50 mu m), 1.5 g of graphene powder (with the particle size of 75 mu m), 1 g of silver powder (with the particle size of 0.1 mu m) and 0.20 g of water-soluble menthol powder (with the particle size of 0.1 mu m) are selected according to corresponding proportions, mixed and stirred for 15 minutes in a mixer (LongYu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukuai City), and then packaged in a vacuum packaging machine and sterilized in a drying and sterilizing manner to obtain the finished product.
Example 8:
112 g of clinoptilolite powder (with the particle size of 30 mu m), 1.5 g of graphene powder (with the particle size of 20 mu m), 1 g of silver powder (with the particle size of 1 mu m) and 0.20 g of water-soluble menthol powder (with the particle size of 1 mu m) are selected according to corresponding proportions, mixed and stirred in a mixer (Longyu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Qufukan city, Shandong province) for 30 minutes at 32-35 ℃, packaged in a vacuum packaging machine, and sterilized by a drying and sterilizing mode to obtain a finished product.
Example 9:
98 g of clinoptilolite powder (with the particle size of 550 mu m), 1 g of graphene powder (with the particle size of 75 mu m), 0.8 g of silver powder (with the particle size of 0.3 mu m) and 0.15 g of water-soluble menthol powder (with the particle size of 0.3 mu m) are selected according to corresponding proportions, mixed and stirred for 20 minutes in a mixer (Longyu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukuai City), packaged in a vacuum packaging machine, and sterilized in a drying and sterilizing manner to obtain a finished product.
Example 10:
98 g of clinoptilolite powder (with the particle size of 850 mu m), 1 g of graphene powder (with the particle size of 50 mu m), 0.8 g of silver powder (with the particle size of 0.8 mu m) and 0.15 g of water-soluble menthol powder (with the particle size of 0.8 mu m) are selected according to corresponding proportions, mixed and stirred for 20 minutes in a mixer (Longyu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukuai City), packaged in a vacuum packaging machine, and sterilized in a drying and sterilizing manner to obtain a finished product.
Example 11:
98 g of clinoptilolite powder (with the particle size of 500 mu m), 1 g of graphene powder (with the particle size of 50 mu m), 0.8 g of silver powder (with the particle size of 0.3 mu m) and 0.15 g of water-soluble menthol powder (with the particle size of 0.3 mu m) are selected according to corresponding proportions, mixed and stirred for 20 minutes in a mixer (Longyu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukuai City), packaged in a vacuum packaging machine, and sterilized in a drying and sterilizing manner to obtain a finished product.
Example 12:
98 g of clinoptilolite powder (with the particle size of 550 mu m), 1 g of graphene powder (with the particle size of 20 mu m), 0.8 g of silver powder (with the particle size of 0.5 mu m) and 0.15 g of water-soluble menthol powder (with the particle size of 0.5 mu m) are selected according to corresponding proportions, mixed and stirred for 20 minutes in a mixer (Longyu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufukuai City), packaged in a vacuum packaging machine, and sterilized in a drying and sterilizing manner to obtain a finished product.
Example 13:
98 g of clinoptilolite powder (with the particle size of 550 mu m), 1 g of graphene powder (with the particle size of 50 mu m), 0.8 g of silver powder (with the particle size of 0.45 mu m) and 0.15 g of water-soluble menthol powder (with the particle size of 0.45 mu m) are selected according to corresponding proportions, mixed and stirred for 20 minutes in a mixer (Longyu medium-sized horizontal spiral mixer, model: LY-Z400, manufacturer: economic development area of Shandong province Qufu City), packaged in a vacuum packaging machine, and sterilized in a drying and sterilizing manner to obtain a finished product.
The zeolite powder is selected from calcium clinoptilolite powder of Hebei Panbao Zeolite science and technology Limited, zeolite ore of the company is in the mouth town of Zhang Jiakou Dushi in Hebei, wherein the grade of two ore layers is more than 85 percent, the porosity is more than 50 percent, the zeolite ore is in the nation, the color is white, no heavy metal is detected, after the zeolite powder is treated at the temperature of 600-650 ℃, 1 percent of calcium chloride is modified into calcium type zeolite, and after the zeolite powder is dried, the calcium type clinoptilolite powder is ultrafine crushed according to the required granularity. For the selection of the particle size of the zeolite powder, the required particle size is obtained by air separation or sieving under practical conditions.
The graphene powder provided above is selected from graphene products of Qingdao rock-ocean carbon materials Co.
The silver powder provided above is selected from the products manufactured by Guangzhou Bokung chemical Co.
The water-soluble menthol powder provided above is selected from products produced by Shaanxi Feisi Biotechnology Co., Ltd, and the liquid of the product is powder prepared by spray drying.
The production places of the selected raw materials are used for ensuring the complete preparation of the hemostatic and effectively verifying the preparation effect and the use effect of the hemostatic.
What this blendor that above-mentioned provided chose to use is the medium-sized horizontal spiral blendor of longYu, the model: LY-Z400, manufacturer: in the economic development area of the mons city of the Shandong province, the mixer is selected, the mixer, the stirrer and the like can well and uniformly stir the selected raw materials, and all mechanical equipment capable of realizing the functions belong to the protection scope of the invention.
The use method comprises the following steps: 1. the wound or bleeding phenomenon of the epidermis of a patient can be bound up only by scattering the hemostatic prepared by the method on the wound surface.
2. The wound or bleeding phenomenon of the vein or artery of the patient can be bandaged only by pressing the hemostatic agent prepared by the method to the wound part needing hemostasis by hands.
A storage mode: the hemostatic agent after vacuum sterilization is packaged and stored in a ventilated and dry environment, and the shelf life of the product is 2 years.
Examples of the experiments
56 healthy New Zealand rabbits (including 28 female New Zealand rabbits and 28 male New Zealand rabbits) which are qualified for quarantine and have the weight of 2.0-3.0kg are selected as experimental objects. The subjects were randomly divided into 14 groups of 4 animals each, and each group was guaranteed to have both male and female halves. The animals were numbered 1-14, with groups 1-13 being experimental and group 14 being control. The experimental group selected the hemostatic agent prepared in the above examples, and the control group selected the hemostatic bag prepared in CN 201910222543.0.
The experimental method comprises the following steps:
during the experiment, each group of experimental objects are anesthetized by 30mg/kg of pentobarbital sodium through ear edge intravenous injection, the patients are completely anesthetized and fixed in a supine position, the groin and the periphery of the right side are unhaired and disinfected, the right femoral artery is separated and exposed, the femoral artery is cut by about 1/2 depth with scissors, the bleeding is stopped by the corresponding experimental group and the control group after freely spraying the blood for 30 seconds, the bleeding is observed every 30 seconds after 1 minute, and the bleeding stopping time and the epidermal temperature of the wound surface during the bleeding stopping are recorded.
The body temperature detection range for New Zealand rabbits in the 2000 edition of the Chinese Biometrics Specification is 38-39.8 ℃.
Experimental reagent:
the experimental group used 350g of hemostatic agent, and the control group used one hemostatic bag prepared in example one.
The results are shown in the following table:
TABLE 1 hemostatic time and hemostatic wound surface epidermal temperature test result table
As can be seen from the data in the above table, in the examples prepared as above, the blood stopping time data and the wound surface epidermis temperature are linearly decreased from example 1 to example 13, wherein the hemostatic effect of examples 12 and 13 is the best, and the treatment temperature for the wound surface epidermis is also low, so that the secondary damage such as slight skin burn of the epidermis is not caused. The hemostatic time required by the hemostatic bag selected in the control group is obviously longer than that of each prepared embodiment, and the temperature reached by the treatment temperature of the hemostatic bag on the wound surface epidermis is easy to cause micro-burn on the wound surface skin of a patient, so that the bleeding volume of the patient is large and the patient is injured additionally.
Clinical cases
Patient 1:
the diseased state is: traumatic hemorrhage due to cutting of blood vessel of wrist artery
The treatment mode comprises the following steps: the hemostatic agent of example 13 prepared as described above was applied to the wound surface and pressed with the palm.
The treatment effect is as follows: the hemostatic agent is pressed and contacted with the wound surface for 15 seconds to complete hemostasis.
Patient 2:
the diseased state is: the length of the finger cut reaches 3 cm, and capillary blood vessels bleed.
The treatment mode comprises the following steps: the hemostatic agent of example 13 prepared as described above was applied to the wound surface and pressed with the palm.
The treatment effect is as follows: the hemostatic agent is pressed and contacted with the wound surface for 10 seconds to complete hemostasis.
The present invention provides a highly effective hemostatic agent prepared by mixing raw materials having a strong selective adsorption ability, a good permeability, a good blood coagulation property and the like and having mild characteristics. The hemostatic agent achieves the effects of diminishing inflammation, inhibiting bacteria, clearing heat and relieving pain by mutual interaction and mutual fusion and effective compatibility of the raw materials, so that quick hemostasis, improvement of coagulation reaction rate, increase of stability of hemostasis effect, quick heat dissipation, reduction of high-temperature burn rate and acceleration of wound healing after the hemostatic agent is contacted with a wound can be achieved in a short time, secondary injury is effectively avoided, and the wound treatment efficiency is improved. The hemostatic agent is safe and reliable, and is suitable for any individual. The preparation method of the hemostatic has the advantages of simple and rapid operation process, less operation equipment, low requirement on operators and moderate cost on the basis of maximally fusing and well storing the effective components of the raw materials after finely selecting the materials.
While particular embodiments of the present invention have been illustrated and described, it will be appreciated that the present invention is not limited to the above-described alternative embodiments, and that various other forms of product may be devised by anyone in light of the present invention. The foregoing detailed description should not be construed as limiting the scope of the invention, and those skilled in the art will understand that various modifications can be made to the technical solutions described in the foregoing embodiments, or some or all of the technical features can be equivalently replaced, without departing from the spirit and scope of the invention, and at the same time, such modifications or replacements do not cause the essence of the corresponding technical solutions to depart from the scope of the technical solutions of the embodiments of the invention; the scope of the invention should be determined with reference to the appended claims, and the description should be construed to interpret the claims.
Claims (10)
1. The efficient hemostatic is characterized by being prepared from the following raw materials in parts by mass:
70-120 parts of zeolite powder, 0.08-2 parts of graphene powder, 0.2-1.5 parts of silver powder and 0.02-0.22 part of water-soluble menthol powder;
preferably, the hemostatic is prepared from the following raw materials in parts by mass:
90-112 parts of zeolite powder, 0.1-1.5 parts of graphene powder, 0.4-1 part of silver powder and 0.08-0.20 part of water-soluble menthol powder;
preferably, the hemostatic is prepared from the following raw materials in parts by mass:
98 parts of zeolite powder, 1 part of graphene powder, 0.8 part of silver powder and 0.15 part of water-soluble menthol powder.
2. The efficient hemostatic agent according to claim 1, wherein the zeolite powder comprises clinoptilolite powder.
3. The efficient hemostatic agent according to claim 1, wherein the zeolite powder has a particle size of 1-1000 μm, preferably 300-850 μm, and more preferably 550 μm.
4. The efficient hemostatic agent according to claim 1, wherein the particle size of the graphene powder is 10-100 μm, preferably 20-75 μm, and more preferably 50 μm.
5. The highly effective hemostatic according to claim 1, wherein the silver powder has a particle size of 0.1-1 μm, preferably 0.3-0.8 μm, and more preferably 0.45 μm.
6. The high-efficiency hemostatic according to claim 1, wherein the particle size of the water-soluble menthol powder is 0.1-1 μm, preferably 0.3-0.8 μm, and more preferably 0.45 μm.
7. The preparation method of the efficient hemostatic agent according to claim 1, wherein the preparation method comprises selecting zeolite powder, graphene powder, silver powder and water-soluble menthol powder according to corresponding proportions, mixing, and sterilizing to obtain a finished product.
8. The method for preparing a high-efficiency hemostatic according to claim 7, wherein the mixing temperature comprises 20-35 degrees Celsius, preferably 25-32 degrees Celsius, and more preferably 30 degrees Celsius.
9. The method for preparing a highly effective hemostatic according to claim 7, wherein the mixing time period comprises 10-35 minutes, preferably 15-30 minutes, and more preferably 20 minutes.
10. The method for preparing a high-potency hemostatic agent according to claim 7, wherein the sterilization comprises one or more of radiation sterilization, dry sterilization, and high-temperature steam sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010015102.6A CN111001033B (en) | 2020-01-07 | 2020-01-07 | High-efficiency hemostatic and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010015102.6A CN111001033B (en) | 2020-01-07 | 2020-01-07 | High-efficiency hemostatic and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111001033A true CN111001033A (en) | 2020-04-14 |
| CN111001033B CN111001033B (en) | 2022-06-21 |
Family
ID=70120632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010015102.6A Active CN111001033B (en) | 2020-01-07 | 2020-01-07 | High-efficiency hemostatic and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111001033B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028284A (en) * | 2007-03-27 | 2007-09-05 | 中国人民解放军第四军医大学 | Externally-applied zeolite hemostat and its preparation |
| CN101181548A (en) * | 2007-12-07 | 2008-05-21 | 北京未名宝生物科技有限公司 | Medicinal or health care composition containing natural antimicrobials |
| CN101357138A (en) * | 2008-07-29 | 2009-02-04 | 浙江大学 | Natural zeolite emergence haemostatic and preparation method thereof |
| CN103191185A (en) * | 2013-04-20 | 2013-07-10 | 江苏迪沃生物制品有限公司 | Antipyretic gel |
| CN107823222A (en) * | 2017-10-25 | 2018-03-23 | 贵安新区瑞诚生物工程有限公司 | Composite nano germicide and its preparation method and application |
| WO2018111949A1 (en) * | 2016-12-12 | 2018-06-21 | Neuronoff, Inc. | Electrode curable and moldable to contours of a target in bodily tissue and methods of manufacturing and placement and dispensers therefor |
| CN109731127A (en) * | 2019-02-27 | 2019-05-10 | 西南交通大学 | A kind of porous styptic sponge and preparation method thereof |
| CN109966543A (en) * | 2019-03-22 | 2019-07-05 | 瞿应良 | A kind of preparation method of wound hemostasis packet and porous hemostat particle |
| CN109999216A (en) * | 2019-05-20 | 2019-07-12 | 北京化工大学 | A kind of trauma hemostasis sponge and its preparation method and application |
-
2020
- 2020-01-07 CN CN202010015102.6A patent/CN111001033B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028284A (en) * | 2007-03-27 | 2007-09-05 | 中国人民解放军第四军医大学 | Externally-applied zeolite hemostat and its preparation |
| CN101181548A (en) * | 2007-12-07 | 2008-05-21 | 北京未名宝生物科技有限公司 | Medicinal or health care composition containing natural antimicrobials |
| CN101357138A (en) * | 2008-07-29 | 2009-02-04 | 浙江大学 | Natural zeolite emergence haemostatic and preparation method thereof |
| CN103191185A (en) * | 2013-04-20 | 2013-07-10 | 江苏迪沃生物制品有限公司 | Antipyretic gel |
| WO2018111949A1 (en) * | 2016-12-12 | 2018-06-21 | Neuronoff, Inc. | Electrode curable and moldable to contours of a target in bodily tissue and methods of manufacturing and placement and dispensers therefor |
| US20190357847A1 (en) * | 2016-12-12 | 2019-11-28 | Neuronoff, Inc. | Electrode curable and moldable to contours of a target in bodily tissue and methods of manufacturing and placement and dispensers therefor |
| CN107823222A (en) * | 2017-10-25 | 2018-03-23 | 贵安新区瑞诚生物工程有限公司 | Composite nano germicide and its preparation method and application |
| CN109731127A (en) * | 2019-02-27 | 2019-05-10 | 西南交通大学 | A kind of porous styptic sponge and preparation method thereof |
| CN109966543A (en) * | 2019-03-22 | 2019-07-05 | 瞿应良 | A kind of preparation method of wound hemostasis packet and porous hemostat particle |
| CN109999216A (en) * | 2019-05-20 | 2019-07-12 | 北京化工大学 | A kind of trauma hemostasis sponge and its preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| FENG, C等: "Chitosan-coated diatom silica as hemostatic agent for hemorrhage control", 《ACS APPLIED MATERIALS & INTERFACES》 * |
| LIANG, YP等: "Eliminating Heat Injury of Zeolite in Hemostasis via Thermal Conductivity of Graphene Sponge", 《ACS APPLIED MATERIALS & INTERFACES》 * |
| 李国峰: "石墨烯基复合材料的外伤止血应用研究", 《中国优秀博士论文全文数据库》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111001033B (en) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Chitosan/kaolin composite porous microspheres with high hemostatic efficacy | |
| CN103800940B (en) | A kind of bleeding-stopping dressing and preparation method | |
| Hu et al. | Antibacterial hemostatic dressings with nanoporous bioglass containing silver | |
| CN101104080B (en) | Zeolite hemostatic dressings and preparation method and application thereof | |
| JP2008531498A (en) | Mineral technology (MT) for emergency hemostasis and treatment of acute wounds and chronic ulcers | |
| US20080097271A1 (en) | Devices and methods for the delivery of hemostatic agents to bleeding wounds | |
| US20080319476A1 (en) | Hemostatic mineral compositions and uses thereof | |
| WO2008034304A1 (en) | Nanometer mesoporous silica-based xerogel styptic material and its preparing process and application | |
| CN101991875A (en) | Mesoporous bioactive glass and chitosan composite porous hemostatic material and preparation method thereof | |
| WO2006012218A1 (en) | Aluminophosphate-based materials for the treatment of wounds | |
| CN102133421A (en) | Rapidly-hemostatic wound dressing as well as preparation method and application thereof | |
| CN105561370B (en) | A kind of hemostatic material and preparation method thereof | |
| CN112451734A (en) | Application of monatomic catalyst as hemostatic agent | |
| Wang et al. | Influence of the physicochemical characteristics of diatom frustules on hemorrhage control | |
| CN114748670B (en) | Nonwoven hemostatic gauze and preparation method and application thereof | |
| CN111617310A (en) | Hemostatic sponge and preparation method and application thereof | |
| CN111001033B (en) | High-efficiency hemostatic and preparation method thereof | |
| Ding et al. | Ca-Ga double doping strategy to fabricate hemostatic mesoporous silica nanoparticles (MSN) with antibacterial activity | |
| Zhang et al. | Fabrication of effective mesoporous silica materials for emergency hemostasis application | |
| CN105477679A (en) | Polysaccharide crosslinking based quick chitosan hemostatic cotton | |
| CN104784742A (en) | Hemostasis dressing and preparation method thereof | |
| CN101357138A (en) | Natural zeolite emergence haemostatic and preparation method thereof | |
| KR102645889B1 (en) | Hemostatic fabric containing trypsin and method for manufacturing the same | |
| CN109453424B (en) | Wound treatment dressing and preparation method thereof | |
| CN106421878A (en) | Rapidly hemostatic and antibacterial carboxylic starch-polylysine microsphere and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |